Claire Sandor currently serves in a Diagnostic Strategy role at Alexion Pharmaceuticals, part of AstraZeneca's Rare Disease Business Unit, since October 2023. Prior to this, Claire held the position of Vice President of Growth at Anova Fertility & Reproductive Health, navigating significant operational challenges during the COVID-19 pandemic. Previous experience includes serving as Business Unit Director for Advanced Diagnostics at LifeLabs Medical Laboratory Services, where Claire led a multidisciplinary team in Genetics and Functional Medicine. Claire has also worked in strategic business development at Centogene AG and has a background as a professional volleyball player, showcasing leadership and teamwork skills. Claire's educational credentials include an MBA/MAE from IAE de Poitiers, Rhetoric and Composition training through edX, and an Honours Bachelor of Science in Human/Medical Genetics from the University of Guelph.